Congress trades

AngioDynamics, Inc. (ANGO)

Medical Instruments & Supplies, listed on NASDAQ.

5 Congress tradeslast filed Oct 24, 2025

Download on the App StoreGet it on Google Play

Free on iOS and Android

EarningsQ1 FY2027 · reported Oct 8, 2026

AngioDynamics beat by 64.4% on adjusted EPS.

-$0.04 a share against a -$0.11 consensus. Revenue $80.9M against $80.5M, in line.

EPS

Reported-$0.04
Consensus-$0.11

Revenue

Reported$80.9M
Consensus$80.5M

Beat 5Miss 1

EPS against the consensus, quarter by quarter. Outlined: a GAAP figure against an adjusted consensus.

Next report Jan 6, 2027. Consensus -$0.11 a share.

Every quarter

Money managers13F filings for Jun 30, 2026

162

institutions reported AngioDynamics shares in 13F filings for Jun 30, 2026. BlackRock, Inc. held the largest stake, $49.5M.

The largest holders

BlackRock, Inc.$49.5M
Systematic Financial Management LP$34.3M
Every holder
Companyfrom the company's filings and listing, as of Nov 8, 2026

About AngioDynamics, Inc.

Exchange
NASDAQ
Sector
Healthcare
Industry
Medical - Instruments & Supplies
Chief executive
James C. Clemmer
Employees
632
Listed since
Jun 1, 2004
Market value
$493.3M
Price to earnings (12 mo)
-
Net income per share, as reported (12 mo)
-$0.78
Dividend yield
-

www.angiodynamics.com

Earnings6 reported quarters · next on Jan 6, 2027

Earnings

QuarterEPSEPS expectedRevenueRevenue expectedResult
Q1 FY2027reported Oct 8, 2026-$0.04-$0.11$80.9M$80.5MEPS beatRevenue in line
Q4 FY2026reported Jul 14, 2026-$0.07-$0.11$86.6M$80.2MEPS beatRevenue beat
Q3 FY2026reported Apr 2, 2026-$0.07-$0.11$78.4M$76.8MEPS beatRevenue beat
Q2 FY2026reported Jan 6, 2026-$0.15-$0.10$79.4M$76.4MEPS miss, GAAPRevenue beat
Q1 FY2026reported Oct 2, 2025-$0.10-$0.14$75.7M$76.3MEPS beatRevenue in line
Q4 FY2025reported Jul 15, 2025-$0.03-$0.13$80.2M$74.3MEPS beatRevenue beat

Actual against the consensus estimate at the time. A flag marks a beat or a miss of more than 1.5% either way; inside that band the quarter is in line. A flag marked GAAP compares a GAAP figure the company reported with an adjusted consensus, two different measures, so a one-time gain or charge can move it either way. A flag reads n/a only when a number is missing. Quarterly EPS is the figure set against the consensus, usually adjusted, so the quarters need not add up to the 12-month net income per share above. An estimate is a forecast made by analysts, not a company target.

Analysts

Analyst ratings and price targets

Past year Each firm's latest target, newest first

Each firm's latest price target on ANGO, newest first
FirmRatingTargetActionDate
H.C. WainwrightBuy$18Cut from $19
CanaccordBuy$20Target set

Each firm's latest target from the past year, with the rating stated with its note. These are the firms' own views, not GetSignal's, and we do not endorse them. Not investment advice.

Ratings and targets come from licensed market data providers. A target is listed only after its firm and company are confirmed against a report of the note. As of Nov 9, 2026.

Proxy statementas filed for fiscal 2026 · proxy filed Oct 8, 2026

Executive pay

James C. Clemmer’s pay as CEO came to $6.1M for fiscal 2026.
ExecutiveSalaryStock awardsOtherTotal
James C. ClemmerPresident, CEO$828K$3.7M$1.5M$6.1M
Stephen A. TrowbridgeEVP, CFO$471K$1.6M$634K$2.7M
Laura PiccininiSVP & GM, Cardiovascular and International$471K$580K$558K$1.6M
Lawrence T. WeissSVP, Chief Legal Officer & Corporate Secretary$439K$553K$502K$1.5M
Warren NighanSVP & GM, Global Supply Chain, Quality and Regulatory Affairs$416K$525K$490K$1.4M

The summary compensation table from the proxy statement for fiscal 2026, with titles as filed then. Executives who have since left are not shown. Read the filing

13F filings13F positions as of Jun 30, 2026

Institutional holders

HolderValueSharesShares vs prior qtr% of shares out
BlackRock, Inc.$49.5M3,803,232+3.2%9.16%
Point72 Asset Management, L.P.Steve Cohen$39.8M3,062,517-3.7%7.37%
Systematic Financial Management LP$34.3M2,640,214+7.6%6.36%
Armistice Capital, LLC$28.6M2,198,000+17.6%5.29%
Royce & Associates LP$25.6M1,969,835+28.8%4.74%
Broadfin Holdings LLC$23.7M1,818,533-12.1%4.38%
Vanguard Capital Management LLC$22.0M1,694,716-1.9%4.08%
Weber Capital Management LLC$17.6M1,356,602-1.2%3.27%
Nuveen, LLC$15.6M1,199,358-1.4%2.89%
Geode Capital Management, LLC$13.3M1,020,658+3.6%2.46%
Dimensional Fund Advisors LP$12.6M969,497+2.2%2.33%
State Street Corp$12.5M958,167-28.2%2.30%

A 13F reports long US equity positions and is filed within 45 days of the quarter end, so these are positions as they stood on Jun 30, 2026. For a manager's whole book see the fund directory. What a 13F covers and leaves out is explained in our guide to Form 13F.

STOCK Act5 disclosures of 5 on record · median 28d of the 45 allowed

Congress trades in ANGO

Since the trade: the stock's move from its estimated entry price (a purchase) or estimated exit price (a sale) to its current price, the latest close we hold. Not the member's result.

MemberTypeActionAmount disclosedSince the tradeTrade dateDisclosedDelay
Debbie Wasserman SchultzDependent childStockSale$2,000.00as listed, not a band-0.8% since the saleEstimated exit price $11.82, close on Mon Oct 20, 2025Current price $11.73, close on Fri Nov 6Oct 20, 2025Oct 24, 20254d
Debbie Wasserman SchultzDependent childStockPurchase$1,001 - $15,000+19.9% since the tradeEstimated entry price $9.78, close on Fri Jun 27, 2025Current price $11.73, close on Fri Nov 6Jun 27, 2025Jul 25, 202528d
Debbie Wasserman SchultzStockSale$1,001 - $15,000+36.4% since the saleEstimated exit price $8.60, close on Wed Jul 16, 2025Current price $11.73, close on Fri Nov 6Jul 16, 2025Jul 25, 20259d
Debbie Wasserman SchultzDependent childStockSale$1,001 - $15,000-27.5% since the saleEstimated exit price $16.19, close on Tue Nov 8, 2016Current price $11.73, close on Fri Nov 6Nov 8, 2016Dec 25, 201647d
Debbie Wasserman SchultzDependent childStockPurchase$1,001 - $15,000-5.6% since the tradeEstimated entry price $12.42, close on Wed Apr 27, 2016Current price $11.73, close on Fri Nov 6Apr 27, 2016Jul 6, 201670d

Estimated prices are the stock's closing price on the trade date. A disclosure gives a value band, not the price paid. Not investment advice. After a sale a positive figure means the stock kept rising after it.

A delay above 45 days is the gap between the dates on the report; we mark a filing late only after checking it.

Every Congress trade in ANGO filterable by party, chamber, type and account.

Congress rows disclose a value range rather than an exact amount, and the STOCK Act allows up to 45 days to report. Full sourcing and the limits of this data are on the methodology page. A filing is a record of a transaction, not a signal, and nothing here is investment advice.

A STOCK Act disclosure gives each trade as a band of dollar values, which we do not narrow, and is due within 45 days of the trade. An option is described by its underlying company's name; its row says it is an option.

Data as of Nov 9, 2026.

Methodology · Guide to Form 4 · Guide to the STOCK Act

Questions

What the filings on ANGO show and how current they are.

Which members of Congress have traded ANGO?

Debbie Wasserman Schultz disclosed ANGO transactions in the filings shown here.

How quickly are ANGO trades disclosed?

Congressional disclosures took a median of 28 days, against the 45 the STOCK Act allows.

Related companies

traded by the same members, or also in Healthcare

See every company we track